Roivant Sciences Ltd.

Valuation Analysis

About the Company

Roivant Sciences Ltd., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines and technologies. Its clinical product candidates include IMVT-1402, a fully human monoclonal antibody targeting FcRn in development across several IgG-mediated autoimmune indications; mosliciguat, an inhaled sGC activator in development for pulmonary hypertension associated with interstitial lung disease; neonatal fragment crystallizable receptor for the treatment of graves' disease, difficult-to-treat rheumatoid arthritis, sjögren's disease, myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, and cutaneous lupus erythematosus indications; batoclimab, a fully human monoclonal antibody for the treatment of thyroid eye disease; and br

Roivant Sciences Ltd. Stock at a Glance

Roivant Sciences Ltd. (ROIV) is currently trading at $30.04 with a market capitalization of $21.6B. The 52-week range spans from $10.71 to $32.79; the current price is 8.4% below the yearly high. Year-over-year revenue growth stands at -66.7%.

💰 Dividend

Roivant Sciences Ltd. currently does not pay a dividend. The company typically reinvests its earnings into growth initiatives and product development.

📊 Analyst Rating

12 analysts rate Roivant Sciences Ltd. (ROIV) on consensus: Strong Buy. The average price target is $39.04, implying +29.97% from the current price. Analyst price targets range from $31.50 to $45.00.

Roivant Sciences Ltd.: The Investment Case in Detail

Roivant Sciences Ltd. (ROIV) operates in the Healthcare — specifically Biotechnology — and is headquartered in United Kingdom. Below is a structured read of the investment case built directly from the latest fundamentals, valuation multiples, analyst positioning and smart-money flows. Each section translates raw numbers into the investment logic they imply, so you can decide whether the risk/reward fits your portfolio.

The Bull Case

Wall Street consensus sits at Strong Buy with an average price target implying roughly 29.97% upside from current levels — analyst sentiment is firmly constructive.

The Bear Case

Revenue is contracting at -66.7% year-over-year — until that trend reverses, valuation is exposed to further downgrades.

What to Watch Next

• The analyst consensus price target implies 29.97% upside — if the next two quarters confirm the underlying thesis, target hikes typically follow.

Investment Thesis: Strengths & Weaknesses

Technical Snapshot

Price trades above both the 50- and 200-day moving averages, with 50d above 200d — a classic bullish setup (golden-cross alignment).

Risk Profile

The data points to market-like volatility, elevated short interest (6.64%).

Trading Data

Related Stocks in the Same Sector

Where can I buy Roivant Sciences Ltd.?

Compare top-rated brokers — low fees, trusted providers, fully regulated.